Xeris Biopharma Holdings Inc

Securities Trading Plans of Directors and Executive Officers

During the three months ended December 31, 2024, none of the Company’s directors or officers adopted, materially modified, orterminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.

Consulting Agreement with Ken Johnson, Senior Vice President, Global Development and Medical Affairs

As previously announced, on February 24, 2025, Dr. Ken Johnson notified the Company of his decision to retire as Senior Vice President, Global Development and Medical Affairs, effective as of April 1, 2025. Dr. Johnson will continue to provide consulting services to the Company following his retirement, as further described below.

In connection with his retirement, the Company and Dr. Johnson entered into a consulting agreement (the “Consulting Agreement”) on March 4, 2025, pursuant to which Dr. Johnson will provide consulting services to the Company following his retirement until February 1, 2026 (the “Consulting Period”). The Consulting Agreement provides that Dr. Johnson will receive a consulting fee (the “Consulting Fee”) of $250.00 per hour during the Consulting Period and that Dr. Johnson must provide a minimum of 200 hours of consulting services during the first six (6) months of the Consulting Period, and fifteen (15) hours of consulting services for the remainder of the Consulting Period. The Company will also reimburse Dr. Johnson for reasonable and necessary expenses incurred in connection with the services during the Consulting Period. The equity awards previously granted to Dr. Johnson will continue to be eligible to vest based on his continued service during the Consulting Period in accordance with their existing terms. Either party may terminate the Consulting Agreement upon a material breach by the other party that remains uncured following thirty (30) days after the date of written notice of such breach, and the Consulting Agreement may be terminated at any time by mutual written agreement of the parties.

The foregoing description of the material terms of the Consulting Agreement for Dr. Johnson does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of which will be filed with the SEC as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.